As it cuts costs and pipeline, Bris­tol My­ers hands back a can­cer drug to Schrödinger

Bris­tol My­ers Squibb will give back a pre­clin­i­cal can­cer drug to Schrödinger, re­turn­ing the SOS1 in­hibitor that was part of a 2020 deal be­tween the com­pa­nies.

The move is part of a cost-cut­ting and pipeline trim­ming ini­tia­tive at Bris­tol My­ers, which is work­ing to re­set its op­er­a­tions un­der new CEO Chris Boern­er. Schrödinger an­nounced the news with its first-quar­ter earn­ings re­sults on Thurs­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER